Columbia University and Project ALS today announced the Project ALS Therapeutics Core at Columbia (THE CORE), a 3-year, $6.3M initiative toward the first meaningful therapies for ALS. THE CORE is the world’s first and only partnership between a world-class academic institution and a leading nonprofit organization dedicated to a full-spectrum approach to ALS drug development, preclinical evaluation, and human clinical trials.
The goal is better clinical trials—and the first effective treatments for people with ALS, a uniformly fatal neurodegenerative disease closely related to Alzheimer’s, Parkinson’s, and Huntington’s diseases. Already, THE CORE has yielded a novel drug, and evaluated dozens of commercial compounds in partnership with pharmaceutical companies.
THE CORE begins and ends with ALS patients—it will utilize patient blood samples toward drug screening, biomarker discovery, and genetics studies, and deliver better therapeutic options back to the clinic, to patients who have participated at the start of the process.
“For the first time, ALS patients can directly participate in research that will move us toward therapies that actually work,” said Neil Shneider, MD, PhD, Director of the Eleanor and Lou Gehrig ALS Center at Columbia. “THE CORE provides an immensely exciting opportunity to capitalize on decades of ALS advances and translate them into meaningful treatments now.”